| Name | Title | Contact Details |
|---|
True Lacrosse is a sports organization founded in 2008 by professional lacrosse players Jake Deane and Mike Gabel, based in Lombard, Illinois. The organization is dedicated to educating and developing young men and women in lacrosse, focusing on creating exceptional athletes while fostering confidence, integrity, and leadership skills. Operating in multiple U.S. states, including Illinois, Colorado, and Michigan, True Lacrosse serves youth players nationwide. The organization emphasizes four core pillars: Passion, Energy, Expertise, and Reps, which guide their training and player development approach. True Lacrosse offers comprehensive training programs that enhance lacrosse skills, game understanding, and athleticism. Their experienced coaching staff, comprised of former professional players, provides valuable insights and support to help players reach their potential and pursue collegiate opportunities. Additionally, True Lacrosse prioritizes player safety by partnering with platforms like HEADCHECK Health to manage concussion risks.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The globally operating Geberit Group is a European leader in the field of sanitary products. Geberit operates as an integrated group with a very strong local presence in many countries, providing unique added value in sanitary technology and bathroom ceramics. The Group is headquartered in Rapperswil-Jona, Switzerland, with a production network encompassing more than 30 production facilities. In North America, Geberit provides concealed systems for wall-hung toilets and fixtures. Geberit systems improve the look of any bathroom by hiding unsightly plumbing hardware. Replacing a standard toilet with the Geberit system results in more usable space, improved hygiene, and better accessibility. The unique dual-flush valve saves water and is practically maintenance-free. Geberit also offers cable-controlled bath waste and overflows in a variety of designer finishes. Critical working parts are outside the waterway, ensuring years of trouble-free operation. With more than 12,000 employees in over 40 countries, Geberit generates net sales of CHF 2.6 billion. The Geberit shares are listed on the SIX Swiss Exchange; since 2012, the Geberit share has been included in the SMI (Swiss Market Index).